Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant radioimmunotherapy with cetuximab in advanced head and neck cancer
2010-019108-22Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Medical University of Vienna. Primary endpoints: Acute radiogenic mucositis rate and Clinical and radiologic response rate. Started Jun 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2010-019108-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019108-22.